Evaluation of the safety and nutritional equivalence of a genetically modified cottonseed meal in a 90-day dietary toxicity study in rats.

Meal prepared from Cry1F/Cry1Ac transgenic/genetically modified cottonseed (WIDESTRIKE Insect Protection, hereafter referred to as WIDESTRIKE) was compared to cottonseed meal prepared from four conventionally bred lines of cotton (three commercial non-transgenic line controls (PHY72, PHY78 and 98M-2983), and a near isoline non-transgenic control (PSC355) in a 90-day dietary study to evaluate safety and nutritional equivalence. Diets were formulated with 10% WIDESTRIKE cottonseed meal equivalent to 7,235 mg/kg/day for males and 7,935 mg/kg/day for females. Animals were evaluated by cage-side and hand-held detailed clinical observations, body weight, and feed consumption. Functional tests, motor activity and ophthalmic examinations were conducted pre-exposure and prior to study termination. Standard hematology, clinical chemistry, prothrombin time and urinalysis parameters were evaluated. All rats had a complete necropsy and selected organs were weighed. Histopathologic examinations were performed on all rats fed the diets containing the near isoline non-transgenic control or WIDESTRIKE. Following 90 days of feeding, no adverse effects were observed during the conduct of clinical observations or in any of the parameters measured in this study. This study demonstrated that rodent diets prepared with 10% cottonseed meal from WIDESTRIKE cottonseeds do not produce any untoward effects and are nutritionally equivalent to cottonseed meals prepared from other, non-transgenic cottonseeds.

Mutational analysis of the H-ras oncogene in spontaneous C57BL/6 x C3H/He mouse liver tumors and tumors induced with genotoxic and nongenotoxic hepatocarcinogens.

The frequency and mutational profile of H-ras gene activation were determined in spontaneous liver tumors of male C57BL/6 x C3H/He mice and in tumors induced with the genotoxic hepatocarcinogen benzidine.2 HCl or the nongenotoxic hepatocarcinogens phenobarbital, chloroform, and ciprofibrate. DNA sequence analysis of the H-ras gene from representative tumors revealed that 32 of 50 (64%) spontaneous tumors and 13 of 22 (59%) benzidine.2 HCl-induced tumors contained a point mutation in codon 61. Tumors induced with the nongenotoxic agents had a much lower frequency of codon 61 mutations, i.e., phenobarbital, 1 of 15 (7%); chloroform, 5 of 24 (21%), and ciprofibrate, 8 of 39 (21%). No mutations were observed at codons 12, 13, and 117 in tumors from any of the groups. Only three base pair substitutions within codon 61 were found. The one most frequently detected in all of the groups was a C.G to A.T transversion at the first nucleotide position, occurring at a 59%, 85%, 100%, 80%, and 88% frequency in the spontaneous tumors and in the tumors induced with benzidine 2.Hcl, phenobarbital, chloroform, and ciprofibrate, respectively. In these same groups an A.T to G.C transition or an A.T to T.A transversion at the second nucleotide position occurred at a frequency of 34%, 8%, 0%, 0%, and 12%, and 6%, 8%, 0%, 20%, and 0%, respectively. The number of tumors carrying an activated H-ras gene in the nongenotoxic treatment groups is within the range that would be expected if those animals had not received any treatment. This indicates that the activation of the H-ras gene in those tumors is probably the result of a spontaneous event. The data suggest that these toxicologically and pharmacologically diverse nongenotoxic hepatocarcinogens increase the frequency of liver tumors but do not induce mutations in the H-ras gene. Instead these agents appear to interact with a population of cells that do not contain an activated H-ras gene. This suggests that the mechanisms of tumor development by these nongenotoxic carcinogens differ at least partially from the mechanisms responsible for the development of spontaneous tumors or those induced by a typical genotoxic agent.

Evaluation of cytotoxicity, cell proliferation, and genotoxicity induced by p-cresidine in hetero- and nullizygous transgenic p53 mice.

The heterozygous p53 knockout mouse is being used as a short-term alternative model for carcinogenicity screening of chemicals. In most cases, these mice develop tumors within 6 months of exposure to genotoxic carcinogens. The bladder and liver carcinogen, p-cresidine, is recommended as a positive control chemical for these assays. To evaluate early effects of p53 deficiency on bladder and liver histopathology and genotoxicity induced by p-cresidine, we treated 4-week-old heterozygous and nullizygous p53 male mice with p-cresidine by gavage (100, 200, 400, and 800 mg/kg/day) 5 days/week for 7 weeks. Tissue sections were prepared for hematoxylin-eosin staining and immunohistochemistry for PCNA protein or 3'-OH DNA fragments to assess cell proliferation and apoptosis, respectively. Blood and bone marrow were examined for methemoglobin and micronuclei in polychromatic erythrocytes (MN-PCE), respectively. Individual cell necrosis of the bladder transitional epithelium was evident in both p53 heterozygous and nullizygous mice at all doses. In addition, diffuse hyperplasia of the bladder epithelium was observed at 400 and 800 mg/kg in both genotypes. In the liver, both genotypes exhibited similar increases in hepatocyte apoptosis (10-fold increase) and cell proliferation (20-fold increase) at 800 mg/kg/day. Methemoglobin levels were increased 6-fold in both genotypes at 800 mg/kg. Background MN-PCE rates were similar in both genotypes and there were no treatment-related increases. Also, no point mutations were observed in codon 12 of the c-Ha-ras gene from urinary bladder DNA from p-cresidine treated p53 mice. These results suggest that loss of p53 allele(s) in mice does not influence the early markers of carcinogenic activity induced by subchronic treatment with p-cresidine. Increased tumor susceptibility associated with a reduction in p53 dosage may be dependent on neoplastic progression rather than initiation and promotional events elicited by p-cresidine.

V-Ha-ras gene expression in liver and kidney of transgenic Tg.AC mice following chemically induced tissue injury.

The dermal Tg.AC transgenic mouse line is currently being used as a short-term alternative in vivo model for carcinogenicity screening of drugs and environmental chemicals. These mice carry multiple copies of an activated v-Ha-ras oncogene, making them susceptible to promotionally induced tumorigenesis caused by carcinogen exposure or deep skin wounding. Transgene expression is associated with tumor development in these animals. To determine whether tissue injury in organs other than the skin can induce transgene expression, we characterized the pattern of transgene expression in naive animals as well as mice treated by oral gavage with cytotoxic doses of chloroform. Hepatic BrdU labeling was increased 40-fold in females (240 mg/kg/day) and 20-fold in males (140 mg/kg/day) after 4 days of dosing with chloroform. An increase in renal BrdU labeling (7-fold) was observed only in male Tg.AC mice. Although chloroform did not induce v-Ha-ras expression, in either the liver or the kidney, a constitutive amount of transgene message was evident in the kidneys of Tg.AC mice. V-Ha-ras transgene expression also correlated with the expression of GATA-3, a transcription factor that binds the zeta-globin (zeta-globin) promoter of the Tg.AC transgene. These studies suggest that chemically induced tissue injury and regenerative cell proliferation per se are not sufficient for the induction of transgene expression in the liver and kidney of Tg.AC mice. Although organs like the kidney may contain the necessary transcription factors for transgene expression, other factors, yet unidentified, may impede v-Ha-ras-mediated tumorigenesis in these tissues.

Lack of carcinogenicity of chlorpyrifos insecticide in a high-dose, 2-year dietary toxicity study in Fischer 344 rats.

Chlorpyrifos (CPF) was administered daily in the feed to evaluate toxicity and oncogenicity potential in male and female Fischer 344 rats, according to U.S. EPA guidelines. Doses for the 2-year study were based on findings in a 13-week feeding study in which lower body weights, urinary perineal staining, adrenal cortical vacuolization, and inhibition (slightly more than 60%) of brain cholinesterase (ChE) occurred at 15 mg/kg/day. The high dose in the subsequent 2-year study was 10 mg/kg/day, with lower doses of 0, 0.05, 0.1, or 1.0 mg/kg/day chosen to define dose-response patterns. Rats given 10 mg/kg/day for 2 years were healthy and there was no evidence of premature deaths. Mild toxicity occurred only in rats given 10 mg/kg/day and consisted of perineal urine soiling in females and a 6-8% body-weight decrease in males. Males given 10 mg/kg/day also had increased adrenal weights and vacuolation of the adrenal zona fasciculata. ChE was considered a measure of exposure. Plasma, RBC, and brain ChE activities were inhibited in rats given 10 mg/kg/day, and the plasma and RBC ChE activities were inhibited in rats given 1.0 mg/kg/day. Chronic exposure to 0.1 mg/kg/day was considered a threshold exposure level for inhibition of plasma ChE. Rats given 10 mg/kg/day, considered a maximum-tolerated dose, had approximately 60% chronic inhibition of brain ChE. This group had similar numbers and types of neoplasms as control rats. Consequently, CPF was not carcinogenic at dose levels up to 10 mg/kg/day.

Spinosad insecticide: subchronic and chronic toxicity and lack of carcinogenicity in Fischer 344 rats.

Spinosad is an insecticide derived from a naturally occurring bacterium via fermentation. The toxicity of spinosad was characterized in subchronic and chronic toxicity/oncogenicity studies conducted according to standard toxicology regulatory guidelines. Subchronic toxicity was evaluated in groups of 10 Fischer 344 rats/sex given feed containing 0, 0.05, 0.1, 0.2, or 0.4% spinosad (Study 1) or 0, 0.003, 0.006, 0.012, or 0.06% spinosad (Study 2) for 13 weeks. Lower body weights and increased mortality occurred in rats given 0.4% spinosad. Microscopic effects were observed in the adrenal glands, liver, lymphoid cells, reproductive tissues, kidney, thyroid, stomach, lung, and skeletal muscle of rats given > or = 0.05% spinosad, and consisted primarily of vacuolation of cells; however, degenerative, regenerative, and/or inflammatory changes were also noted in some tissues. Vacuolation within a number of tissues was ultrastructurally characterized by an increase in size and number of lysosomes that contained extensive membranous whorls consistent with phospholipidosis. The no observed effect level (NOEL) in the 13-week studies was 0.012% (24 mg/kg/day) spinosad. Chronic toxicity and oncogenicity were evaluated in groups of 60 Fischer 344 rats/sex given feed containing 0, 0.005, 0.02, 0.05, or 0.1% spinosad for up to 2 years. Rats given 0.1% spinosad for 1 year had microscopic effects similar to those observed in the subchronic studies. Vacuolation and inflammation of the thyroid gland also occurred in rats given 0.05% spinosad for 1 year. Excessive mortality occurred in rats from the oncogenicity study given 0.1% spinosad by 21 months, and surviving rats were euthanized because the maximum tolerated dose had been exceeded. Rats given 0.05% spinosad for 2 years had vacuolation and/or inflammation involving the thyroid, lymphoid tissue, and lung. Rats given 0.05% spinosad had similar numbers of neoplasms as control rats, indicating that spinosad was not carcinogenic at dose levels up to 0.05%. The NOEL at 2 years was 0.005% (2.4 mg/kg/day) spinosad.

Mode of action considerations in the use of transgenic animals for mutagenicity and carcinogenicity evaluations.

Genetically altered rodent models can be useful in facilitating the extrapolation of results from animal carcinogenicity studies to human risk assessment by contributing mode of action data. Transgenic mutation models make it possible to analyze mutations in vivo in any tissue of interest. Validation studies using genotoxic and epigenetic carcinogens indicated a good correlation between mutation induction and the tumor target tissues and have provided data on mode of tumorigenic action. However, carcinogenesis is a complex process and mutation induction in a given tissue does not always lead to tumors in that tissue. Genetically altered animal models such as the p53 +/- mouse can be useful in differentiating genotoxic carcinogens from those operating by non-genotoxic mechanisms. An understanding of the tumor responses of these short-term alternative transgenic and knockout mice to epigenetic events such as tissue injury and enzyme induction at high maximum tolerated doses will eventually increase our level of confidence in these animal models for hazard evaluation and mechanistic studies.

Neurobehavioral effects of dietary restriction in rats.

The effects of reduced body weight gain on nervous system function of young male Fischer 344 rats were examined. The rats were fed 15% ('mild') or 50% ('severe') less than the controls. Mild and severe dietary restriction resulted in 9% and 38% lower body weight compared to the controls. Mild dietary restriction caused slight changes in flash evoked potentials, auditory brainstem responses, caudal nerve action potentials, and body temperature. Severe dietary restriction increased the magnitude of the effects noted in the mild group, as well as causing a significant decrease in grip strength. Somatosensory evoked responses were not affected by either mild or severe restriction. Diet restricted rats were more excitable while restrained for testing. Thus, dietary restriction has significant effects on numerous behavioral and neurophysiological parameters that should be considered in the interpretation of neurotoxicological data when body weight differences are present.

Neurotoxicologic examination of rats exposed to 1,1,2,2-tetrachloroethylene (perchloroethylene) vapor for 13 weeks.

Large evoked potential and EEG changes occurred in a pilot study in Fischer 344 rats during exposure to 800 ppm of 1,1,2,2-tetrachloroethylene [perchloroethylene (Perc)], a cleaning solvent with anesthetic properties. In the main study, rats were evaluated for persistent nervous system effects the week following exposure to 0, 50, 200, or 800 ppm Perc for 6 h/day, 5 days/week, for 13 weeks. The only effect related to treatment was in the flash evoked potential (FEP-V), recorded from the visual cortex. The longer latency potentials (N3) of the FEP-V had a greater amplitude in the 800 ppm Perc group. The FEP-Vs were of normal shape and latency. Although mild neurotoxicity could not be ruled out completely, amplitude changes in N3 can occur for a variety of psychophysiological reasons other than neurotoxicity. Consequently, as a stand-alone finding, the toxicologic significance of the larger FEP in the 800 ppm exposure group was unknown. Other data did not support a diagnosis of neurotoxicity. No treatment-related alterations were noted in expanded clinical observations, in the FEP recorded from the cerebellum (as opposed to visual cortex FEP-V), or in auditory, somatosensory, or caudal nerve evoked potentials. No treatment-related lesions were noted during histopathologic examination of eyes, optic nerves, optic tract, or multiple sections of brain, spinal cord, peripheral nerves, or limb muscles. The no-observed-effect-level (NOEL) was 200 ppm, based on increased amplitude of the longer latency potentials of the FEP at 800 ppm.

Developmental toxicity of Spinosad administered by gavage to CD rats and New Zealand white rabbits.

The insecticide Spinosad was administered by gavage to pregnant CD(R) rats at 0, 10, 50 or 200 mg/kg/day on gestation days (gd) 6-15 and to New Zealand White rabbits at 0, 2.5, 10 or 50 mg/kg/day on gd-7-19. Rats and rabbits were monitored for clinical signs of toxicity and body weight gains. At gd-21 (rats) or gd-28 (rabbits), maternal organ weights, reproductive parameters, fetal body weights, and fetal external, visceral and skeletal structures were evaluated. Rats given 200 mg/kg/day exhibited a 4% lower body weight on gd-12 and decreased body weight gains on gd-6-16 relative to controls. There was no maternal toxicity at 10 or 50 mg/kg/day, and no developmental toxicity in rats at any dose level. Rabbits given 50 mg/kg/day exhibited decreased feed consumption, reduced fecal output, body weight loss during the initial dosing period (gd-7-10) and a non-statistically significant decrease (31%) in body weight gain during the dosing period (gd-7-20). Two litters aborted due to maternal inanition. There were no maternal effects at lower doses, and no signs of developmental toxicity at any dose. Thus, the maternal no-observed-effect levels (NOEL) were 50 and 10 mg/kg/day in rats and rabbits, respectively, and the embryonal/fetal NOELs were 200 mg/kg/day in rats and 50 mg/kg/day in rabbits.

Natural remission of nephrotic syndrome in a dog with immune-complex glomerular disease.

A nephrotic syndrome caused by immune-complex glomerular disease was diagnosed in a 4-year-old male Great Dane. The syndrome was characterized by proteinuria, hypoproteinemia, hypoalbuminemia, hypercholesterolemia, and subcutaneous edema. Renal biopsy revealed segmental membranous glomerular disease. The edema underwent complete remission 18 days after admission. Two months after admission, there was no clinical or laboratory evidence of glomerular disease. Periodic reevaluation of the dog during the next 2 years revealed recurrence of proteinuria, but no other clinical or laboratory abnormalities. Serial renal biopsies revealed persistence, but no appreciable increase, in the severity of the segmental membranous glomerular disease. The natural course of the nephrotic syndrome and immune-complex glomerular disease has been associated with unpredictable variability. It was concluded that the widespread use of corticosteroid or immunosuppressant therapy in dogs with immune complex glomerular disease should be withheld until the natural course of the disease has been evaluated in a significant number of patients and until the results of well-controlled clinical studies confirm or deny their therapeutic value.

Systemic mastocytoma associated with lymposarcoma in an aged cat.

Systemic mastocytoma was diagnosed in a 16 year old cat. Prednisone therapy was initiated but discontinued after 11 months because of development of a duodenal ulcer. Twenty months after the initial diagnosis the cat developed dyspnea, due to enlarged pharyngeal lymph nodes. Euthanasia was performed; systemic mastocytoma and lymphosarcoma were found at necropsy.

Nitrapyrin: a scientific advisory group review of the mode of action and carcinogenicity in B6C3F1 mice.

Nitrapyrin has been registered as a nitrogen stabilizer in the United States for many years based on a robust set of regulatory data. These data demonstrated that nitrapyrin was not genotoxic and that there were no tumors elicited in rats or mice that were relevant for human risk assessment. A repeat carcinogenicity study in B6C3F1 mice, conducted at two substantially higher-dose levels (0, 125 or 250 mg/kg/day) than the original study (0, 5, 25 or 75 mg/kg/day) identified liver, stomach, epididymal and Harderian gland tumors. In order to assess the relevance of these findings for human risk assessment, a Scientific Advisory Group (SAG) examined relevant microscopic changes in these tissues and also evaluated genotoxicity and mechanistic data. The SAG determined that the maximum tolerated dose had been exceeded in mice given 125 or 250 mg/kg/day, based on 26-33% decreased body weight gains (males-250 mg/kg/day), hepatocellular necrosis and compensatory hepatocellular proliferation (males and females-125 and 250 mg/kg/day). The SAG believed that the increased incidences of hepatocellular foci of alteration and hepatocellular neoplasms represented an epigenetic response to hepatocellular necrosis and increased mitogenesis. Increased incidences of proliferative lesions in the forestomach mucosa were likely secondary to the irritant effects of nitrapyrin. Neither the liver nor forestomach effects were interpreted to be a direct carcinogenic effect. Higher incidences of Harderian gland adenomas (females) and undifferentiated sarcomas in the epididymis represented normal biological variations in incidence and were unrelated to nitrapyrin. Therefore, it was the SAG's opinion that nitrapyrin exposure that does not produce target organ toxicity in exposed individuals would not be expected to increase the risk of cancer.

Dipropylene glycol monomethyl ether: a 13-week inhalation toxicity study in rats and rabbits.

Fischer 344 rats (10/sex/exposure concentration) and New Zealand White rabbits (7/sex/exposure concentration) were exposed to 0, 15, 50, or 200 ppm (0, 91, 303, or 1212 mg/m3) of dipropylene glycol monomethyl ether (DPGME) for 6 hr/day, 5 days/week for 13 weeks. Criteria of response included general observations, body weights, clinical chemistry, hematology, urinalyses (rats only), necropsy, organ weights, and histopathology. There were no effects attributed to exposure to DPGME at any exposure concentration in either male or female rats or rabbits. The highest concentration tested (200 ppm) was approximately 40% of a saturated DPGME atmosphere. Based on the low vapor pressure of DPGME, and results in this 13-week study, DPGME appears to have a low subchronic vapor inhalation toxicity hazard.

Propylene glycol monomethyl ether: a 13-week inhalation toxicity study in rats and rabbits.

Fischer 344 rats (10/sex/exposure concentration) and New Zealand White rabbits (7/sex/exposure concentration) were exposed to 0, 300, 1000, or 3000 ppm (0, 1.09, 3.62, or 10.9 mg/L) of propylene glycol monomethyl ether (PGME) for 6 hr/da, 5 da/wk, for 13 weeks. Minimal effects were observed in animals exposed to 3000 ppm. Indications of a transient central nervous system depression were observed in rats and rabbits exposed to 3000 ppm. There were also small increases (6 to 8%) in mean relative liver weights of 3000 ppm exposed male and female rats relative to controls. Minimal histologic effects were observed in the livers of 3000 ppm exposed female rats. These were suggestive of hepatocellular hypertrophy but were without evidence of degenerative changes. There was an increase in the urinary pH of male rats exposed to 3000 ppm PGME for 4 weeks, but this was not evident after 12 weeks of exposure. There was no indication of histopathological effects in the kidneys of either species, and there were no hematological effects. No treatment-related effects were found in either rats or rabbits exposed to 300 or 1000 ppm.

Feline insular amyloid: histochemical distinction from secondary systemic amyloid.

Amyloid in islets of Langerhans from 48 domestic cats, one human, one non-human primate, and one raccoon was compared with secondary systemic amyloid from three domestic cats, one dog, one human, and one cow to determine affinity for Congo red dye after treatment of paraffin-embedded tissue sections with potassium permanganate and dilute sulfuric acid. Insular amyloid from all six species was resistant to pretreatment with potassium permanganate, i.e., affinity for Congo red was retained, whereas secondary systemic amyloid from all species was sensitive to the potassium permanganate pretreatment. Other stains did not distinguish between insular and secondary systemic amyloid. The potassium permanganate-Congo red staining procedure thus can be used to differentiate insular from secondary systemic amyloid in the cat and other species. The results also indicate that insular amyloid and secondary systemic amyloid are of different chemical composition and pathogenesis.

Feline insular amyloid. Ultrastructural evidence for intracellular formation by nonendocrine cells.

The objective of this ultrastructural study in cats was to investigate the early relationship of pancreatic islet cells with amyloid deposits. We used pancreatic islets from six domestic cats with minimal and apparently early amyloid deposits. Although amyloid deposits were occasionally arranged perpendicularly to beta cells, and rarely within deep invaginations of these cells, there was no consistent or convincing relationship of extracellular fibrils to any of the major islet stricted to, nongranulated perivascular cells in islets from two of the cats. Small and relatively electron-dense amyloid inclusions contained compact arrays of parallel fibrils. Larger inclusions were more electron-lucent and had loosely and randomly arranged fibrils. Indirect evidence strongly suggested that the fibril-laden inclusions resulted from intracellular production rather than from phagocytosis. The definitive identity of these amyloid-containing cells was not determined. However, these calls lacked secretory granules specific for known islet endocrine cell types and were topographically always located in close proximity to capillaries. The results of our study, therefore, do not directly support a morphologic association of amyloid fibril formation with typical islet endocrine cells. Our results do, however, draw attention to the possibility that nonendocrine cells play a key role in the pathogenesis of insular amyloidosis in the cat.